Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

The Interplay Between Nutrition and Stress in Pregnancy: Implications for Fetal Programming of Brain Development.

Lindsay KL, Buss C, Wadhwa PD, Entringer S.

Biol Psychiatry. 2018 Jul 4. pii: S0006-3223(18)31635-4. doi: 10.1016/j.biopsych.2018.06.021. [Epub ahead of print] Review.

PMID:
30057177
2.

Maternal Metabolomic Profile and Fetal Programming of Offspring Adiposity: Identification of Potentially Protective Lipid Metabolites.

Hellmuth C, Lindsay KL, Uhl O, Buss C, Wadhwa PD, Koletzko B, Entringer S.

Mol Nutr Food Res. 2018 Apr 30:e1700889. doi: 10.1002/mnfr.201700889. [Epub ahead of print]

PMID:
29714050
3.

Pregnancy Exercise and Nutrition With Smartphone Application Support: A Randomized Controlled Trial.

Kennelly MA, Ainscough K, Lindsay KL, OʼSullivan E, Gibney ER, McCarthy M, Segurado R, DeVito G, Maguire O, Smith T, Hatunic M, McAuliffe FM.

Obstet Gynecol. 2018 May;131(5):818-826. doi: 10.1097/AOG.0000000000002582.

PMID:
29630009
4.

Maternal metabolic response to dietary treatment for impaired glucose tolerance and gestational diabetes mellitus.

Lindsay KL, Brennan L, Kennelly MA, Curran S, Coffey M, Smith TP, Foley ME, Hatunic M, McAuliffe FM.

Ir J Med Sci. 2018 Aug;187(3):701-708. doi: 10.1007/s11845-018-1744-y. Epub 2018 Jan 20.

PMID:
29353417
5.

Gestational weight gain in obese pregnancy: impact on maternal and foetal metabolic parameters and birthweight.

Lindsay KL, Brennan L, Rath A, Maguire OC, Smith T, McAuliffe FM.

J Obstet Gynaecol. 2018 Jan;38(1):60-65. doi: 10.1080/01443615.2017.1328670. Epub 2017 Aug 6.

PMID:
28782412
6.

Behaviour change in overweight and obese pregnancy: a decision tree to support the development of antenatal lifestyle interventions.

Ainscough KM, Lindsay KL, O'Sullivan EJ, Gibney ER, McAuliffe FM.

Public Health Nutr. 2017 Oct;20(14):2642-2648. doi: 10.1017/S136898001700129X. Epub 2017 Jul 10. Review.

PMID:
28691650
7.

The Interplay between Maternal Nutrition and Stress during Pregnancy: Issues and Considerations.

Lindsay KL, Buss C, Wadhwa PD, Entringer S.

Ann Nutr Metab. 2017;70(3):191-200. doi: 10.1159/000457136. Epub 2017 Mar 17. Review.

8.

Influences on the food choices and physical activity behaviours of overweight and obese pregnant women: A qualitative study.

O'Brien OA, Lindsay KL, McCarthy M, McGloin AF, Kennelly M, Scully HA, McAuliffe FM.

Midwifery. 2017 Apr;47:28-35. doi: 10.1016/j.midw.2017.02.003. Epub 2017 Feb 7.

PMID:
28236733
9.

The association between childcare and risk of childhood overweight and obesity in children aged 5 years and under: a systematic review.

Alberdi G, McNamara AE, Lindsay KL, Scully HA, Horan MH, Gibney ER, McAuliffe FM.

Eur J Pediatr. 2016 Oct;175(10):1277-94. doi: 10.1007/s00431-016-2768-9. Epub 2016 Sep 8. Review.

PMID:
27631590
10.

Association of maternal prepregnancy BMI with metabolomic profile across gestation.

Hellmuth C, Lindsay KL, Uhl O, Buss C, Wadhwa PD, Koletzko B, Entringer S.

Int J Obes (Lond). 2017 Jan;41(1):159-169. doi: 10.1038/ijo.2016.153. Epub 2016 Aug 29.

PMID:
27569686
11.

Nutrition During Pregnancy Impacts Offspring's Epigenetic Status-Evidence from Human and Animal Studies.

Geraghty AA, Lindsay KL, Alberdi G, McAuliffe FM, Gibney ER.

Nutr Metab Insights. 2016 Feb 16;8(Suppl 1):41-7. doi: 10.4137/NMI.S29527. eCollection 2015. Review.

12.

Longitudinal Metabolomic Profiling of Amino Acids and Lipids across Healthy Pregnancy.

Lindsay KL, Hellmuth C, Uhl O, Buss C, Wadhwa PD, Koletzko B, Entringer S.

PLoS One. 2015 Dec 30;10(12):e0145794. doi: 10.1371/journal.pone.0145794. eCollection 2015.

13.

Fetal metabolic influences of neonatal anthropometry and adiposity.

Donnelly JM, Lindsay KL, Walsh JM, Horan M, Molloy EJ, McAuliffe FM.

BMC Pediatr. 2015 Nov 10;15:175. doi: 10.1186/s12887-015-0499-0.

14.

Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial.

Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, Curran S, Coffey M, Foley ME, Hatunic M, Shanahan F, McAuliffe FM.

Am J Obstet Gynecol. 2015 Apr;212(4):496.e1-11. doi: 10.1016/j.ajog.2015.02.008. Epub 2015 Feb 14.

PMID:
25687568
15.

Reply to C Griffin.

Lindsay KL, Brennan L, McAuliffe FM.

Am J Clin Nutr. 2014 Oct;100(4):1209-10. doi: 10.3945/ajcn.114.094425. No abstract available.

PMID:
25240086
16.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.

Lancet. 2014 Nov 15;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9. Epub 2014 Jul 28. Erratum in: Lancet. 2014 Nov 15;384(9956):1748.

PMID:
25078309
17.

Pregnant immigrant Nigerian women: an exploration of dietary intakes.

Lindsay KL, Gibney ER, McNulty BA, McAuliffe FM.

Public Health. 2014 Jul;128(7):647-53. doi: 10.1016/j.puhe.2014.05.001.

PMID:
25065518
18.

Lifestyle and dietary habits of an obese pregnant cohort.

Lindsay KL, Heneghan C, McNulty B, Brennan L, McAuliffe FM.

Matern Child Health J. 2015 Jan;19(1):25-32. doi: 10.1007/s10995-014-1491-2.

PMID:
24740724
19.

Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study).

Lindsay KL, Kennelly M, Culliton M, Smith T, Maguire OC, Shanahan F, Brennan L, McAuliffe FM.

Am J Clin Nutr. 2014 Jun;99(6):1432-9. doi: 10.3945/ajcn.113.079723. Epub 2014 Mar 19.

PMID:
24646819
20.

Acceptability of and compliance with a probiotic capsule intervention in pregnancy.

Lindsay KL, Brennan L, McAuliffe FM.

Int J Gynaecol Obstet. 2014 Jun;125(3):279-80. doi: 10.1016/j.ijgo.2014.01.004. Epub 2014 Feb 19. No abstract available.

PMID:
24636629
21.

Probiotics in pregnancy and maternal outcomes: a systematic review.

Lindsay KL, Walsh CA, Brennan L, McAuliffe FM.

J Matern Fetal Neonatal Med. 2013 May;26(8):772-8. doi: 10.3109/14767058.2012.755166. Epub 2013 Jan 11. Review.

PMID:
23205866
22.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

23.

Maternal nutrition among women from Sub-Saharan Africa, with a focus on Nigeria, and potential implications for pregnancy outcomes among immigrant populations in developed countries.

Lindsay KL, Gibney ER, McAuliffe FM.

J Hum Nutr Diet. 2012 Dec;25(6):534-46. doi: 10.1111/j.1365-277X.2012.01253.x. Epub 2012 May 18. Review.

PMID:
22594552
24.

Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.

Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group.

J Viral Hepat. 2012 Jun;19(6):404-13. doi: 10.1111/j.1365-2893.2011.01562.x. Epub 2011 Dec 16.

25.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

26.

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP.

Gastroenterology. 2011 Jun;140(7):1961-9. doi: 10.1053/j.gastro.2011.02.061. Epub 2011 Mar 2.

27.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group.

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

28.

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ; HALT-C Trial Group.

J Affect Disord. 2011 Mar;129(1-3):205-12. doi: 10.1016/j.jad.2010.09.010.

29.

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

Roberts SS, Miller RK, Jones JK, Lindsay KL, Greene MF, Maddrey WC, Williams IT, Liu J, Spiegel RJ.

Birth Defects Res A Clin Mol Teratol. 2010 Jul;88(7):551-9. doi: 10.1002/bdra.20682.

PMID:
20564430
30.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group.

Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744.

31.

Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.

Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, Kronfol Z; HALT-C Trial Group.

Am J Gastroenterol. 2010 Jul;105(7):1551-60. doi: 10.1038/ajg.2010.3. Epub 2010 Jan 26.

32.

Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Dec;50(6):1738-49. doi: 10.1002/hep.23211.

33.

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. Erratum in: Gastroenterology. 2010 Mar;138(3):1215.

34.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

35.

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Aug;137(2):549-57. doi: 10.1053/j.gastro.2009.05.007. Epub 2009 May 13.

36.

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877.

37.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

38.

Hepatitis C virus: a critical appraisal of approaches to therapy.

Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N.

Clin Gastroenterol Hepatol. 2009 Apr;7(4):397-414; quiz 366. doi: 10.1016/j.cgh.2008.11.016. Epub 2008 Nov 21. Review. No abstract available.

PMID:
19114127
39.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

40.

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group.

Gastroenterology. 2009 Jan;136(1):138-48. doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18.

41.

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM; HALT-C Trial Group.

Hepatology. 2008 Nov;48(5):1412-9. doi: 10.1002/hep.22487.

42.

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok AS, Stoddard AM; HALT-C Trial Group.

Am J Gastroenterol. 2008 Nov;103(11):2766-75. doi: 10.1111/j.1572-0241.2008.02106.x. Epub 2008 Aug 21.

43.

Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.

Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG; HALT-C Trial.

Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41. doi: 10.1016/j.cgh.2007.11.020.

PMID:
18237873
44.

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group.

Hepatology. 2008 Feb;47(2):605-12.

45.

Inadequate numbers.

Lindsay KL, Greene MF, Jones JK, Maddrey WC, Miller RK.

Can Fam Physician. 2007 Mar;53(3):401; author reply 401-2. No abstract available.

46.

Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C.

Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok AS, Fontana RJ; Halt-C Trial Group.

J Int Neuropsychol Soc. 2007 Jul;13(4):687-92. Epub 2007 May 18.

PMID:
17521478
47.

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.

Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L; HALT-C Trial Group.

Hepatology. 2007 May;45(5):1154-63.

48.

Intrahepatic lymphocyte phenotypes in hepatitis C virus infection: a comparison between cirrhotic and non-cirrhotic livers.

Bonacini M, Govindarajan S, Kohla M, Lai MM, Lindsay KL.

Minerva Gastroenterol Dietol. 2007 Mar;53(1):1-7.

PMID:
17415341
49.

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C; HALT-C Trial Group.

Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54.

PMID:
17296533
50.

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR.

Gastroenterology. 2007 Jan;132(1):103-12. Epub 2006 Nov 11.

PMID:
17241864

Supplemental Content

Loading ...
Support Center